UPB
Upstream Bio, Inc.
$5.73
-0.02
(-0.35%)
Mkt Cap
311.83M
Volume
501,306
52W Range
5.65-33.68
Sector
Healthcare
Beta
1.29
EPS (TTM)
-2.90 USD
P/E Ratio
-10.21
Revenue (TTM)
3.16M USD
Rev Growth (5Y)
+33.0%
EPS Growth (5Y)
N/A
Company Description
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 2.85M | 2.37M | 2.38M | 1.21M |
| Net Income | (143.44M) | (62.81M) | (20.54M) | (23.87M) |
| EPS | -2.66 | -1.49 | -1.05 | -0.66 |
| Free Cash Flow | (133.28M) | (59.68M) | (38.07M) | (19.10M) |
| FCF / Share | -2.47 | -1.16 | -1.05 | -0.53 |
| Operating CF | (133.28M) | (59.17M) | (37.93M) | (19.02M) |
| Total Assets | 353.77M | 481.72M | 117.20M | 18.48M |
| Total Debt | 1.27M | 1.83M | 45,000 | 94,000 |
| Cash & Equiv | 101.58M | 325.89M | 25.83M | 17.05M |
| Book Value | 339.77M | 469.85M | (123.13M) | (106.16M) |
| Return on Equity | -0.42 | -0.13 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 773,000 | 1.03M | 668,000 | 683,000 | 937,000 | 566,000 | 613,000 | 607,000 | 510,000 | 640,000 | 450,000 | 621,000 |
| Net Income | (39.70M) | (40.59M) | (42.46M) | (33.75M) | (39.97M) | (27.27M) | (21.24M) | (15.99M) | (14.68M) | (10.89M) | (11.83M) | (3.10M) |
| EPS | -0.73 | -0.75 | -0.79 | -0.63 | -0.74 | -0.51 | -0.41 | -0.41 | -0.38 | -0.27 | -0.41 | -0.17 |
| Free Cash Flow | (35.62M) | (47.85M) | (30.68M) | (22.19M) | (39.29M) | (41.16M) | (19.80M) | (14.29M) | (8.04M) | (17.56M) | (16.11M) | (4.82M) |
| FCF / Share | -0.65 | -0.88 | -0.57 | -0.41 | -0.73 | -0.77 | -0.39 | -0.28 | -0.16 | -0.34 | -0.44 | -0.13 |
| Operating CF | (35.62M) | (47.85M) | (30.63M) | (22.24M) | (39.24M) | (41.16M) | (19.61M) | (13.96M) | (8.04M) | (17.56M) | (16.11M) | (4.82M) |
| Total Assets | 281.17M | 318.05M | 353.77M | 391.19M | 420.52M | 456.17M | 481.72M | 232.70M | 244.51M | 0 | 117.20M | N/A |
| Total Debt | 954,000 | 1.11M | 1.27M | 1.42M | 1.56M | 1.70M | 1.83M | 1.94M | 0 | 0 | 45,000 | N/A |
| Cash & Equiv | 79.40M | 96.72M | 101.58M | 72.16M | 45.46M | 71.31M | 325.89M | 32.95M | 47.34M | 109.81M | 25.83M | N/A |
| Book Value | 270.96M | 304.00M | 339.77M | 378.58M | 408.74M | 445.61M | 469.85M | (160.31M) | (146.61M) | 107.81M | (123.13M) | N/A |
| Return on Equity | -0.15 | -0.13 | -0.12 | -0.09 | -0.10 | -0.06 | -0.05 | N/A | N/A | -0.10 | N/A | N/A |
UPB News
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Fannie Mae Announces Sale of Non-Performing Loans
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026